Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma

Yasufumi Goto, Kazuo Koyanagi, Norihiko Narita, Yutaka Kawakami, Minoru Takata, Aya Uchiyama, Linhda Nguyen, Tung Nguyen, Xing Ye, Donald L. Morton, Dave S B Hoon

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Fatty acid-binding protein-7 (FABP7) has been shown to be expressed in cutaneous melanoma; however, its role in tumor progression is unclear. Expression of FABP7 was assessed during melanoma progression through assessment of various clinicopathology stages of primary tumor progression and metastasis. FABP7 mRNA was highly expressed in 60 of 87 (69%) primary melanomas, compared with significant (P0.0001) reduction in 13 of 68 (19%) metastatic melanomas. Analysis of 37 paired primary and metastatic melanomas by immunohistochemistry with anti-FABP7 Ab showed 73 and 27% positivity, respectively (P0.001). FABP7 detection of metastatic tissues was inversely correlated with relapse-free (P0.0001) and overall (P0.0001) survival. To examine FABP7 expression loss in advanced melanomas, loss of heterozygosity (LOH) was assessed using microsatellite markers encompassing the FABP7 gene. LOH was identified in 10 of 20 (50%) metastatic melanomas at 6q22.31, compared with 0 of 14 primary melanomas (P0.0017). FABP7 as a surrogate biomarker for circulating tumor cells (CTCs) in the blood was assessed by quantitative real-time (qRT)-PCR from melanoma patients blood (n134). Assessment of patients blood showed that FABP7() CTC decreased with disease progression. FABP7 may function as a tumor progression gene and can be used as a potential diagnostic biomarker of early-stage melanoma systemic spreading in blood.

Original languageEnglish
Pages (from-to)221-229
Number of pages9
JournalJournal of Investigative Dermatology
Volume130
Issue number1
DOIs
Publication statusPublished - 2010 Jan

Fingerprint

Fatty Acid-Binding Proteins
Gene expression
Melanoma
Gene Expression
Tumors
Blood
Circulating Neoplastic Cells
Loss of Heterozygosity
Biomarkers
Genes
Cutaneous Malignant Melanoma
Fatty Acid-Binding Protein 7
Neoplasms
Microsatellite Repeats
Disease Progression
Real-Time Polymerase Chain Reaction
Immunohistochemistry
Cells
Tissue
Neoplasm Metastasis

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Goto, Y., Koyanagi, K., Narita, N., Kawakami, Y., Takata, M., Uchiyama, A., ... Hoon, D. S. B. (2010). Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. Journal of Investigative Dermatology, 130(1), 221-229. https://doi.org/10.1038/jid.2009.195

Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. / Goto, Yasufumi; Koyanagi, Kazuo; Narita, Norihiko; Kawakami, Yutaka; Takata, Minoru; Uchiyama, Aya; Nguyen, Linhda; Nguyen, Tung; Ye, Xing; Morton, Donald L.; Hoon, Dave S B.

In: Journal of Investigative Dermatology, Vol. 130, No. 1, 01.2010, p. 221-229.

Research output: Contribution to journalArticle

Goto, Y, Koyanagi, K, Narita, N, Kawakami, Y, Takata, M, Uchiyama, A, Nguyen, L, Nguyen, T, Ye, X, Morton, DL & Hoon, DSB 2010, 'Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma', Journal of Investigative Dermatology, vol. 130, no. 1, pp. 221-229. https://doi.org/10.1038/jid.2009.195
Goto, Yasufumi ; Koyanagi, Kazuo ; Narita, Norihiko ; Kawakami, Yutaka ; Takata, Minoru ; Uchiyama, Aya ; Nguyen, Linhda ; Nguyen, Tung ; Ye, Xing ; Morton, Donald L. ; Hoon, Dave S B. / Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma. In: Journal of Investigative Dermatology. 2010 ; Vol. 130, No. 1. pp. 221-229.
@article{8fa85d10c8354ef3bb527d8029698d7f,
title = "Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma",
abstract = "Fatty acid-binding protein-7 (FABP7) has been shown to be expressed in cutaneous melanoma; however, its role in tumor progression is unclear. Expression of FABP7 was assessed during melanoma progression through assessment of various clinicopathology stages of primary tumor progression and metastasis. FABP7 mRNA was highly expressed in 60 of 87 (69{\%}) primary melanomas, compared with significant (P0.0001) reduction in 13 of 68 (19{\%}) metastatic melanomas. Analysis of 37 paired primary and metastatic melanomas by immunohistochemistry with anti-FABP7 Ab showed 73 and 27{\%} positivity, respectively (P0.001). FABP7 detection of metastatic tissues was inversely correlated with relapse-free (P0.0001) and overall (P0.0001) survival. To examine FABP7 expression loss in advanced melanomas, loss of heterozygosity (LOH) was assessed using microsatellite markers encompassing the FABP7 gene. LOH was identified in 10 of 20 (50{\%}) metastatic melanomas at 6q22.31, compared with 0 of 14 primary melanomas (P0.0017). FABP7 as a surrogate biomarker for circulating tumor cells (CTCs) in the blood was assessed by quantitative real-time (qRT)-PCR from melanoma patients blood (n134). Assessment of patients blood showed that FABP7() CTC decreased with disease progression. FABP7 may function as a tumor progression gene and can be used as a potential diagnostic biomarker of early-stage melanoma systemic spreading in blood.",
author = "Yasufumi Goto and Kazuo Koyanagi and Norihiko Narita and Yutaka Kawakami and Minoru Takata and Aya Uchiyama and Linhda Nguyen and Tung Nguyen and Xing Ye and Morton, {Donald L.} and Hoon, {Dave S B}",
year = "2010",
month = "1",
doi = "10.1038/jid.2009.195",
language = "English",
volume = "130",
pages = "221--229",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma

AU - Goto, Yasufumi

AU - Koyanagi, Kazuo

AU - Narita, Norihiko

AU - Kawakami, Yutaka

AU - Takata, Minoru

AU - Uchiyama, Aya

AU - Nguyen, Linhda

AU - Nguyen, Tung

AU - Ye, Xing

AU - Morton, Donald L.

AU - Hoon, Dave S B

PY - 2010/1

Y1 - 2010/1

N2 - Fatty acid-binding protein-7 (FABP7) has been shown to be expressed in cutaneous melanoma; however, its role in tumor progression is unclear. Expression of FABP7 was assessed during melanoma progression through assessment of various clinicopathology stages of primary tumor progression and metastasis. FABP7 mRNA was highly expressed in 60 of 87 (69%) primary melanomas, compared with significant (P0.0001) reduction in 13 of 68 (19%) metastatic melanomas. Analysis of 37 paired primary and metastatic melanomas by immunohistochemistry with anti-FABP7 Ab showed 73 and 27% positivity, respectively (P0.001). FABP7 detection of metastatic tissues was inversely correlated with relapse-free (P0.0001) and overall (P0.0001) survival. To examine FABP7 expression loss in advanced melanomas, loss of heterozygosity (LOH) was assessed using microsatellite markers encompassing the FABP7 gene. LOH was identified in 10 of 20 (50%) metastatic melanomas at 6q22.31, compared with 0 of 14 primary melanomas (P0.0017). FABP7 as a surrogate biomarker for circulating tumor cells (CTCs) in the blood was assessed by quantitative real-time (qRT)-PCR from melanoma patients blood (n134). Assessment of patients blood showed that FABP7() CTC decreased with disease progression. FABP7 may function as a tumor progression gene and can be used as a potential diagnostic biomarker of early-stage melanoma systemic spreading in blood.

AB - Fatty acid-binding protein-7 (FABP7) has been shown to be expressed in cutaneous melanoma; however, its role in tumor progression is unclear. Expression of FABP7 was assessed during melanoma progression through assessment of various clinicopathology stages of primary tumor progression and metastasis. FABP7 mRNA was highly expressed in 60 of 87 (69%) primary melanomas, compared with significant (P0.0001) reduction in 13 of 68 (19%) metastatic melanomas. Analysis of 37 paired primary and metastatic melanomas by immunohistochemistry with anti-FABP7 Ab showed 73 and 27% positivity, respectively (P0.001). FABP7 detection of metastatic tissues was inversely correlated with relapse-free (P0.0001) and overall (P0.0001) survival. To examine FABP7 expression loss in advanced melanomas, loss of heterozygosity (LOH) was assessed using microsatellite markers encompassing the FABP7 gene. LOH was identified in 10 of 20 (50%) metastatic melanomas at 6q22.31, compared with 0 of 14 primary melanomas (P0.0017). FABP7 as a surrogate biomarker for circulating tumor cells (CTCs) in the blood was assessed by quantitative real-time (qRT)-PCR from melanoma patients blood (n134). Assessment of patients blood showed that FABP7() CTC decreased with disease progression. FABP7 may function as a tumor progression gene and can be used as a potential diagnostic biomarker of early-stage melanoma systemic spreading in blood.

UR - http://www.scopus.com/inward/record.url?scp=72049127502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049127502&partnerID=8YFLogxK

U2 - 10.1038/jid.2009.195

DO - 10.1038/jid.2009.195

M3 - Article

C2 - 19587692

AN - SCOPUS:72049127502

VL - 130

SP - 221

EP - 229

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 1

ER -